Jean-Luc Vachiéry, Marius M Hoeper, Andrew J Peacock, Olivier Sitbon, Martino Cheli, Colin Church, Karen M Olsson, Massimiliano Palazzini, Brian Waterhouse, Jonathan Langley, Nazzareno Galié
BACKGROUND: The VOLibris Tracking (VOLT) Study was an open-label, prospective, observational, multicenter, post-marketing registry program designed to more fully characterize the safety profile of ambrisentan for the treatment of pulmonary arterial hypertension (PAH). The key outcome was the incidence of aminotransferase elevations >3× the upper limit of normal (ULN). METHODS: In total, 999 patients from 115 centers in 15 countries, who were prescribed ambrisentan for the treatment of PAH (Functional Class II and III) between 30 June 2008 and 13 May 2011, were enrolled...
April 2017: Journal of Heart and Lung Transplantation